Chargement en cours...
Rituximab in post-transplant pediatric recurrent focal segmental glomerulosclerosis
BACKGROUND: Focal segmental glomerulosclerosis (FSGS) recurs in 20–40 % of allografts. Plasmapheresis (TPE) has been one of the mainstays of treatment with variable results. Rituximab (RTX), a monoclonal antibody to the protein CD20, is being used for treatment of recurrent FSGS (recFSGS) but pediat...
Enregistré dans:
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3541458/ https://ncbi.nlm.nih.gov/pubmed/23052653 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00467-012-2314-6 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|